Literature DB >> 31188340

Successful reintroduction of tumour necrosis factor-alpha inhibition after treatment of disseminated Lyme borreliosis.

Naomi S Bulteel1, Clark D Russell2,3, Meghan R Perry2,4, Oliver Koch2.   

Abstract

The importance of tumour necrosis factor-alpha (TNF-α) in the human immune response to Borrelia burgdorferi is uncertain. Murine models suggest a critical role, including spirochaete reactivation following TNF-α inhibition. Our case, combined with a review of the clinical and scientific literature, provides reassurance that TNF-α inhibition can be safely reinstituted after treatment of disseminated borreliosis with standard duration antimicrobial chemotherapy.

Entities:  

Keywords:  Borrelia; certolizumab; immunotherapy; tumour necrosis factor-alpha

Mesh:

Substances:

Year:  2019        PMID: 31188340     DOI: 10.4997/JRCPE.2019.207

Source DB:  PubMed          Journal:  J R Coll Physicians Edinb        ISSN: 1478-2715


  1 in total

1.  Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alfa Inhibitors.

Authors:  Vera Maraspin; Petra Bogovič; Tereza Rojko; Katarina Ogrinc; Eva Ružić-Sabljić; Franc Strle
Journal:  J Clin Med       Date:  2019-11-02       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.